← Leaderboards
Deborah L Toppmeyer
Univ Of Med/Dent Nj-R W Johnson Med Sch
$870,317
Attributed
$870,317
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$870,317 · 2
By mechanism
R01$791,854 · 1
R21$78,463 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- Leroy F Liu$9,409,862
- William N Hait$3,322,304
- Irving E Vega$5,433,484
- Jonathan D. Dinman$9,353,302
- Bing Xia$11,519,463
Others in their field
Top investigators on “P53 Gene /Protein”
- Carol Prives · Icahn School Of Medicine At Mount Sinai$12,538,956
- Margaret R. Wrensch · University Of California San Francisco$6,944,039
- Andrei V Gudkov · University Of Illinois At Chicago$6,669,890
- Tyler E Jacks · Massachusetts Institute Of Technology$5,782,860
- Timothy J Yeatman · University Of South Florida$5,430,738
- Lawrence A. Donehower · Baylor College Of Medicine$4,852,912
Research focus
P53 Gene /ProteinDrug Screening /EvaluationWomen'S HealthClinical ResearchDoxorubicinFemaleHuman SubjectMicrotubule Associated ProteinPharmacokineticsVinca AlkaloidsBreast NeoplasmsSds Polyacrylamide Gel ElectrophoresisVinblastineDosageWestern BlottingsPolymerase Chain ReactionFluorescent In Situ HybridizationGene ExpressionCombination ChemotherapyNeoplasm /Cancer ChemotherapyNeoplasm /Cancer GeneticsClinical Trial Phase IiPatient Oriented ResearchDna Damage
Grant awards (4)
Phase II Doxorubicin/Vinorelbine in wtp53 Breast Cancer$268,397
R01 · FY2005 · CA
Phase II Doxorubicin/Vinorelbine in wtp53 Breast Cancer$268,397
R01 · FY2004 · CA
Phase II Doxorubicin/Vinorelbine in wtp53 Breast Cancer$255,060
R01 · FY2003 · CA
SEQUENTIAL DOXORUBICIN AND VINORELBINE IN BREAST CANCER$78,463
R21 · FY2000 · CA